Digital Innovation Meets Cardiovascular Care: Longenesis Partners with Novartis

Introduction to Longenesis

Longenesis is a digital health start-up co-founded by Emil Syundyukov and based in Riga, Latvia. The company’s mission is to accelerate therapies by leveraging health data to improve patient outcomes. Longenesis has empowered nearly one million patients in ten therapeutic areas across Europe, the Middle East, and Africa.

In 2023, Longenesis achieved significant recognition by winning 2nd place in the Digital Health category of the EIT Health Catapult program, alongside an Industry Award from Amazon Web Services. The start-up has also raised €2 million in investments, notably backed by LongeVC, a venture fund dedicated to advancing longevity biotech. LongeVC's backing underscores the potential of Longenesis’ innovations to not only address cardiovascular health but also contribute to the broader goals of extending human healthspan and improving quality of life.

Project Goal

The project aims to create a dynamic digital registry for patients with heart failure and dyslipidemia. This registry will facilitate faster and more effective treatments by providing doctors with a comprehensive overview of patients’ evolving conditions.

The project will achieve this by:

• Identifying high-risk patients faster to enable timely treatment, as the digital registry will provide real-time updates on patient conditions.

• Streamlining clinical research by facilitating the collection and analysis of real-time patient data, which can accelerate treatment insights.

• Enabling data-driven care to support healthcare professionals in making informed decisions and improving patient outcomes.

Key Context:

• Dyslipidemia is a condition characterized by abnormal lipid (cholesterol or triglyceride) levels in the blood, which is a major risk factor for cardiovascular diseases.

• The project will leverage patient data across multiple EU countries, ensuring broader research insights and healthcare improvements.

• This project serves as a test phase before scaling the solution to the Baltics and Europe.

Why This Matters

Cardiovascular disease (CVD) is leading cause of death in Europe:

• 37% of all deaths in the European Union are due to CVD.

• In the broader European region (including non-EU countries), this figure rises to 45%.

The economic burden of CVD is profound, costing the EU €210 billion annually:

• Healthcare expenses: Direct costs for treatments, hospitalizations, and medical services.

• Productivity losses: Economic losses due to premature deaths or work disability.

• Informal care: The cost of unpaid care provided by family members or caregivers.

A Promising Future for Longevity Biotech

The collaboration between Longenesis, Novartis, and Daugavpils Regional Hospital highlights the pivotal role of digital health technologies in addressing pressing healthcare challenges. As cardiovascular diseases remain a key area of focus, initiatives like this not only align with the goals of the longevity biotech industry but also provide a glimpse into a future where digital solutions can help extend healthy lifespans